Electrophysiology & Arrhythmia

U.K.-based startup Cambridge Heartware has announced the launch of its company and its first product, a wearable heart monitor powered by artificial intelligence, in early 2019.

The implantable cardioverter defibrillator (ICD) market is projected to grow to $4.3 billion by 2028, with compound annual growth of 4.1 percent, according to a new report from GlobalData.

A trial designed to test the effectiveness of additional antibiotic prophylaxis before and after cardiac electronic device implantation found that such an approach did not significantly lower the rate of subsequent infections, although there was a trend in that direction.

Cardiologs co-founder and CEO Yann Fleureau was named the European Innovator of the Year by MIT Technology Review. The company offers a cloud-based artificial intelligence (AI) platform that enables the detection of 14 cardiac arrhythmias through ambulatory electrocardiogram (ECG) readings.

It takes emergency medical services (EMS) almost four minutes longer to transport cardiac arrest patients from poor neighborhoods to the hospital versus those from high-income neighborhoods, according to a study of 2014 United States EMS data published in JAMA Network Open.

Atrial fibrillation could be an independent predictor of worse outcomes in heart patients with implantable cardioverter-defibrillators (ICDs), according to a meta-analysis published this November in the Journal of the American Heart Association.

Regardless of clinical and socioeconomic factors, black patients with atrial fibrillation (AF) are significantly less likely than whites and Hispanics to receive appropriate treatment with oral anticoagulants (OACs), researchers reported Nov. 28 in JAMA Cardiology.

People who experience out-of-hospital cardiac arrest (OHCA) are nearly twice as likely to survive if they are transferred directly to a hospital with 24-hour capability to perform PCI or targeted temperature management (TTM) versus another center, according to a meta-analysis published Nov. 28 in the Journal of the American Heart Association.

When consumers think of wearable personal health devices, they likely picture smartwatches or other wrist-worn gadgets. But as Forbes pointed out in a Nov. 26 article, new headphone-type wearables—dubbed “hearables”—have already grown into a $5 billion market and offer unique capabilities.

Almost 1 in 5 patients are rehospitalized within 30 days of undergoing catheter ablation of MI-associated ventricular tachycardia (VT), according to a study from the Nationwide Readmissions Database. These patients rack up 38.9 percent higher cumulative hospital costs than those who aren’t readmitted, researchers reported in Circulation: Arrhythmia and Electrophysiology.

Monitoring digoxin concentration and platelet activation in atrial fibrillation (AF) patients treated with vitamin K antagonists could be important for reducing those patients’ inherently elevated risk for CVD, according to a study published in the Journal of the American Heart Association Nov. 15.

Half a decade of planning and millions of dollars have culminated in the Alliance for Cardiovascular Diagnostic and Treatment Innovation (ADVANCE), a joint engineering and cardiology center launched by Johns Hopkins University in an attempt to improve the diagnosis and treatment of a range of arrhythmia disorders.